A personalized liquid biopsy assay named MRD4U has been developed for pediatric central nervous system tumor tracking, achieving unprecedented sensitivity. This advancement, soon to be detailed in BMC Cancer, promises earlier detection and improved disease monitoring, significantly impacting pediatric oncology care paradigms.